ArticleCancers2010
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer.Frontiers in oncology · 2024Review
- Copy Number Variation of Circulating Tumor DNA (ctDNA) Detected Using NIPT in Neoadjuvant Chemotherapy-Treated Ovarian Cancer Patients.Frontiers in genetics · 2022Article
- Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma.Frontiers in oncology · 2022Article
- High Expression ofFrontiers in oncology · 2022Article
- The Anterior GRadient (AGR) family proteins in epithelial ovarian cancer.Journal of experimental & clinical cancer research : CR · 2021Review
- Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors.Journal of ovarian research · 2018Article
- Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.British journal of cancer · 2018Article
- Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.Scientific reports · 2017Article
- The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.International journal of oncology · 2016Article
- Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.World journal of hepatology · 2015Review
- Lesser-Known Molecules in Ovarian Carcinogenesis.BioMed research international · 2015Review
- Expression of the MT1 melatonin receptor in ovarian cancer cells.International journal of molecular sciences · 2014Article
- OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.Molecular cancer · 2014Article
- Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.Journal of cellular physiology · 2014Review
- Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.International scholarly research notices · 2014Review
- Ovarian cancer: in search of better marker systems based on DNA repair defects.International journal of molecular sciences · 2013Review
- New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.BioMed research international · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer is the most lethal gynecological malignancy. Due to its lack of symptoms, this disease is diagnosed at an advanced stage when the cancer has already spread to secondary sites. While initial rates of response to first treatment is >80%, the overall survival rate of patients is extremely low, mainly due to development of drug resistance. To date, there are no reliable clinical factors that can properly stratify patients for suitable chemotherapy strategies. Clinical parameters such as disease stage, tumor grade and residual disease, although helpful in the management of patients after their initial surgery to establish the first line of treatment, are not efficient enough. Accordingly, reliable markers that are independent and complementary to clinical parameters are needed for a better management of these patients. For several years, efforts to identify prognostic factors have focused on molecular markers, with a large number having been investigated. This review aims to present a summary of the recent advances in the identification of molecular biomarkers in ovarian cancer patient tissues, as well as an overview of the need and importance of molecular markers for personalized medicine in ovarian cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.